How is heparin therapy monitored clinically?

• A. PT
• B. Bleeding time
• C. aPTT or anti-Xa in some protocols
• D. Platelet count

Answer: (C)

When treating with unfractionated heparin, how strong the anticoagulant effect is must be measured with tests that reflect heparin’s action in the body. The most common is the activated partial thromboplastin time, which lengthens when heparin is present because heparin inhibits thrombin and factor Xa via antithrombin III. Clinicians adjust the infusion to keep the aPTT within a therapeutic range, which is set by the lab and protocol and can vary.

In some protocols, a more direct measure of heparin activity is used: anti-Xa. This assay quantifies how much factor Xa’s activity is inhibited by heparin-antithrombin complexes, giving a direct readout of heparin effect. Anti-Xa monitoring can be preferred when aPTT results are unreliable due to patient factors or laboratory variability, offering a clearer assessment of anticoagulation.

PT is not used to monitor heparin because it assesses the extrinsic pathway and vitamin K–dependent factors, not the heparin-dependent pathways. Bleeding time isn’t a reliable or standard measure of anticoagulation. Platelet count matters for detecting HIT and overall bleeding risk, but it does not quantify the anticoagulant effect of heparin.